Acid control with esomeprazole and lansoprazole: A comparative dose–response study

References

• Joelsson B, Johnsson F. Heartburn: the acid test. Gut 1989; 30: 1523–5
   PubMed Web of Science ®Google Scholar
• Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986; 8 Suppl 1: 52–8
   PubMed Web of Science ®Google Scholar
• Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118–24
   PubMed Web of Science ®Google Scholar
• Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 695–710
   PubMed Web of Science ®Google Scholar
• Vaezi MF. “Refractory GERD”: acid, nonacid, or not GERD?. Am J Gastroenterol 2004; 99: 989–90
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68: 184–8
   PubMed Web of Science ®Google Scholar
• Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004; 24: 1–7
   PubMed Web of Science ®Google Scholar
• Katz PO, Xue S, Castell DO. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther 2001; 15: 647–52
   PubMed Web of Science ®Google Scholar
• Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA. Dose–response relationship of lansoprazole to gastric acid antisecretory effects. Aliment Pharmacol Ther 1998; 12: 321–7
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149–58
   PubMed Web of Science ®Google Scholar
• Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231–4
   PubMed Web of Science ®Google Scholar
• Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763–7
   PubMed Web of Science ®Google Scholar
• Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux diseases on health-related quality of life. Arch Intern Med 2001; 161: 45–52
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg, in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531–9
   PubMed Web of Science ®Google Scholar
• Miner P, Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616–20
   PubMed Web of Science ®Google Scholar
• Harder H, Teyssen S, Stephan F, Pfutzer R, Kiel G, Fuchs W, et al. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand J Gastroenterol 1999; 34: 551–61
   PubMed Web of Science ®Google Scholar
• Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238–43
   PubMed Web of Science ®Google Scholar
• Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl 1: 59–67
   PubMed Web of Science ®Google Scholar
• Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649–57
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. Am J Gastroenterol 2002; 97: 575–83
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Deviere J, Bigard MA, Bayerdörffer E, Mozsik G, Murray F, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333–41
   PubMed Web of Science ®Google Scholar
• Geus WP, Mulder PG, Nicolai JJ, Van den Boomgaard DM, Lamers CB. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998; 12: 329–35
   PubMed Web of Science ®Google Scholar
• Wilder-Smith, CH, Schindler, D, Nilsson-Pieschl, C, Lundin, C, Röhss, K. Is switching between proton pump inhibitors (PPIs) reasonable? An intraindividual analysis of cross-sensitivity to PPIs [abstract]. Gut 2002;51(Suppl III):A170.
   Google Scholar